| DC67244 |
AS01 |
A combination of immunostimulants QS-21 and MPL with liposomes |
|
| DC67245 |
AS02 |
A combination of immunostimulants QS-21 and MPL with an oil in water emulsion |
|
| DC67246 |
AS03 |
A combination of an oil in water emulsion with alpha-tocopherol (Vitamin E) as immuno-enhancing component |
|
| DC67247 |
AS04 |
MPL is adsorbed onto aluminum hydroxide or aluminum phosphate, depending on the vaccine with which it is used |
|
| DC67248 |
AS15 |
A combination of immunostimulants CpG 7909, QS-21 and MPL with liposomes |
|
| DC67249 |
MF59 |
MF59 represents a highly efficacious oil-in-water emulsion adjuvant, renowned for its commendable safety profile and its capacity to mitigate immunosenescence—the age-associated decline in immune function—particularly in the elderly population. Primarily engineered for incorporation into influenza vaccines, MF59-adjuvanted formulations have demonstrated superior efficacy in eliciting robust immune responses among older adults when juxtaposed with conventional inactivated influenza vaccines. The adjuvant's formulation is characterized by squalene droplets, meticulously stabilized with minimal quantities of the surfactants Tween 80 and Span 85. This unique composition not only augments the immunogenic potential of influenza antigens but also broadens the spectrum of the immune response. It achieves this by enhancing cross-reactivity against viral strains that are not explicitly represented within the vaccine, thereby offering a more comprehensive protective umbrella against influenza. |
|
| DC67250 |
CAF01 (Cationic Adjuvant Formulation 01) |
CAF01 (Cationic Adjuvant Formulation 01) is a lipid-based adjuvant system comprising cationic liposome dimethyldioctadecylammonium bromide (DDA) and immunomodulator trehalose 6,6'-dibehenate (TDB). It enhances antigen-specific immune responses, particularly Th1-type cellular immunity, by stabilizing cationic liposomes for antigen delivery and activating innate immunity via TDB's interaction with receptors like Mincle.
CAF01 has shown promise in vaccine development, especially for tuberculosis, by boosting immunogenicity and inducing durable immune memory. Its proven safety and biocompatibility in clinical trials support its potential for human vaccine applications. In summary, CAF01 is a versatile and effective adjuvant, offering robust immune enhancement for novel vaccine strategies. |
|
| DC67251 |
CAF09 (Cationic Adjuvant Formulation 09) |
CAF09 (Cationic Adjuvant Formulation 09) is a novel liposome-based vaccine adjuvant system composed of the cationic liposome dimethyldioctadecylammonium bromide (DDA), the immunostimulant trehalose 6,6'-dibehenate (TDB), and the TLR3 agonist polyinosinic-polycytidylic acid (Poly(I:C )). This combination endows CAF09 with unique immunomodulatory properties, enabling it to simultaneously activate both innate and adaptive immune responses, particularly demonstrating remarkable efficacy in inducing robust Th1 and CD8+ T cell responses.
CAF09 enhances antigen uptake and presentation through its cationic liposome structure, while TDB activates C-type lectin receptors (such as Mincle) to amplify innate immune signaling. Additionally, Poly(I:C ) further strengthens immune activation via the TLR3 pathway. This multimodal immunostimulatory mechanism allows CAF09 to significantly enhance antigen immunogenicity and induce broad immune protection, encompassing both humoral and cellular immunity.
Research has shown that CAF09 holds great potential in the development of various vaccines, particularly for viral infections and cancer immunotherapy. Its potent immune-enhancing effects and favorable safety profile have been validated in preclinical studies, laying a solid foundation for its future application in human vaccine development. In summary, CAF09, as a highly effective and multifunctional adjuvant, provides robust technical support for the design and optimization of next-generation vaccines. |
|
| DC67252 |
Quil A |
Quil A, a natural saponin adjuvant derived from Quillaja saponaria bark, is known for its strong immunostimulatory effects. It promotes Th1 immunity and cytotoxic T cell responses by enhancing antigen uptake and cytokine release. Widely used in veterinary vaccines (e.g., for foot-and-mouth disease and rabies), its natural form can be toxic, leading to purified or modified versions like QS-21 to reduce side effects. Recently, Quil A has shown promise in human vaccines, particularly for cancer and antiviral applications, due to its unique immune-boosting properties. In summary, Quil A is a versatile adjuvant with significant potential in both animal and human vaccine development. |
|
| DC67253 |
Montanide 206 |
Montanide 206 is a water-in-oil-in-water (W/O/W) emulsion adjuvant by SEPPIC, enhances antigen immunogenicity and induces long-lasting immune responses by prolonging antigen release at the injection site. Suitable for vaccines requiring strong humoral and cellular immunity, it is widely used in veterinary vaccines (e.g., foot-and-mouth disease, swine fever) and shows promise in human vaccines, particularly for cancer and infectious diseases. Known for its biocompatibility, low toxicity, and ease of use, Montanide ISA 206 is a versatile adjuvant for vaccines needing potent and durable immune responses. |
|
| DC67254 |
Montanide 51 |
Montanide 51 is a water-in-oil (W/O) emulsion-based vaccine adjuvant developed by SEPPIC. It creates a stable oil-phase microenvironment that prolongs antigen retention at the injection site, enhancing antigen immunogenicity and inducing potent immune responses. Montanide ISA 51 is particularly suitable for vaccines requiring strong cellular and humoral immunity, such as cancer vaccines and therapeutic vaccines.
This adjuvant is characterized by its high immune-enhancing capacity, excellent stability, and compatibility with various antigens. Montanide ISA 51 has shown remarkable efficacy in cancer vaccine development, effectively activating antigen-specific T cell responses and promoting anti-tumor immunity. Additionally, it has been used in research for vaccines against infectious diseases, such as HIV and malaria.
In summary, Montanide ISA 51, as an efficient water-in-oil adjuvant, provides critical technical support for the development of therapeutic and cancer vaccines through its unique sustained-release mechanism and immune-enhancing properties. It is particularly effective in scenarios requiring robust cellular immune responses. |
|
| DC67255 |
Montanide 50 |
Montanide 50 is a water-in-oil (W/O) emulsion-based vaccine adjuvant developed by SEPPIC. It forms a stable oil-phase microenvironment that prolongs antigen retention at the injection site, enhancing antigen immunogenicity and inducing potent immune responses. Montanide ISA 50V is particularly suitable for vaccines requiring robust cellular and humoral immunity, such as cancer vaccines and therapeutic vaccines.
This adjuvant is characterized by its high immune-enhancing capacity, excellent stability, and compatibility with various antigens. Montanide ISA 50V has demonstrated significant efficacy in cancer vaccine development, effectively activating antigen-specific T cell responses and promoting anti-tumor immunity. Additionally, it has been utilized in research for vaccines against infectious diseases, such as HIV and malaria.
In summary, Montanide ISA 50V, as an efficient water-in-oil adjuvant, provides critical technical support for the development of therapeutic and cancer vaccines through its unique sustained-release mechanism and immune-enhancing properties. It is particularly effective in scenarios requiring strong cellular immune responses. |
|
| DC67256 |
LAS-OI01 |
LAS-OI01 is a novel LNP (Lipid Nanoparticle) vaccine adjuvant and immunotherapeutic agent that combines a dual-adjuvant molecular system comprising CpG 2007 (a TLR9 agonist) and a TLR7/8 activator. This combination elicits robust and long-lasting cellular and humoral immune responses, significantly enhancing the immunogenicity of vaccines. The LNP lipid nanoparticles optimize the uptake and activation of immune cells by efficiently delivering antigens and adjuvant molecules, thereby improving the strength and durability of immune responses.
This adjuvant system is suitable for a wide range of animal vaccines, including those for pigs, cattle, sheep, horses, chickens, ducks, geese, fish, dogs, and cats. It demonstrates particularly notable efficacy in vaccines against complex pathogens such as bacteria, viruses, fungi, and parasites. Research indicates that LNP lipid nanoparticles can enhance the immunostimulatory effects of CpG 2007 by 5-10 times, while the inclusion of the TLR7/8 activator further synergistically boosts Th1-type immune responses and antibody production.
In summary, the LNP lipid nanoparticle adjuvant system, with its efficient delivery capability and dual-adjuvant synergy, provides powerful technical support for animal vaccines and immunotherapy. It excels in scenarios requiring strong immune protection against complex pathogen infections. |
|
| DC67257 |
LAS-OI03 |
LAS-OI03 is a novel LNP (Lipid Nanoparticle) vaccine adjuvant and immunotherapeutic agent that combines a dual-adjuvant molecular system comprising CpG 1018 (a TLR9 agonist) and a TLR7/8 activator. This combination elicits robust and long-lasting cellular and humoral immune responses, significantly enhancing the immunogenicity of vaccines. The LNP lipid nanoparticles optimize the uptake and activation of immune cells by efficiently delivering antigens and adjuvant molecules, thereby improving the strength and durability of immune responses.
This adjuvant system is suitable for the development of various human prophylactic and therapeutic vaccines, particularly demonstrating notable efficacy in vaccines against complex pathogens such as bacteria, viruses, fungi, and parasites. Research indicates that LNP lipid nanoparticles can enhance the immunostimulatory effects of CpG 1018 by 5-10 times, while the inclusion of the TLR7/8 activator further synergistically boosts Th1-type immune responses and antibody production.
In summary, the LNP lipid nanoparticle adjuvant system, with its efficient delivery capability and dual-adjuvant synergy, provides powerful technical support for human vaccines and immunotherapy. It excels in scenarios requiring strong immune protection against complex pathogen infections. |
|
